向日葵(300111.SZ):貝得藥業部分業務需要搬遷 擬落户杭州灣上虞經開區產業拓展區
格隆匯1月28日丨向日葵(300111.SZ)公佈,根據紹興市相關政策扶持,公司控股子公司浙江貝得藥業有限公司(“貝得藥業”)部分業務需要搬遷,為響應政府實現產業集中集聚集約和經濟高質量發展,貝得藥業與杭州灣上虞經濟技術開發區管理委員會(浙江省上虞經濟開發區管理委員會)於2022年1月28日簽署了《項目落户協議》,擬落户杭州灣上虞經濟技術開發區產業拓展區,建設藥物製劑和原料藥項目,計劃總投資7億元(以有關建設項目備案和實際投資情況為準),擬總用地167.5畝。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.